知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

117 records (took 0.031 seconds)

    USE OF COMPOUNDS WITH THROMBOPOIETIC ACTIVITY TO PROMOTE BONE GROWTH AND HEALING
    93.
    发明申请
    USE OF COMPOUNDS WITH THROMBOPOIETIC ACTIVITY TO PROMOTE BONE GROWTH AND HEALING 审中-公开
    使用化学物质与血栓形成活动促进骨骼生长和治疗

    公开(公告)号：US20130149349A1

    公开(公告)日：2013-06-13

    申请号：US13700904

    申请日：2011-06-03

    Applicant: Melissa A. Kacena ,  Tien-Min Gabriel Chu

    Inventor： Melissa A. Kacena ,  Tien-Min Gabriel Chu

    IPC: A61L27/54

    CPC classification number: A61K38/196 ,  A61K9/0024 ,  A61K45/06 ,  A61L27/54 ,  C07K14/524 ,  C07K2319/30

    Abstract: TPO was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap. Scaffolds that included TPO promoted better outcomes than scaffolds that included BMP-2 or scaffolds that did not include either TPO or BMP-2. These data indicate that compounds that exhibit thrombopoietic activity such a recombinant TPO can be used to promote bone growth and healing in mammals.

    Abstract translation: TPO用于促进大鼠和小鼠中骨骼的生长。 用小鼠和大鼠骨骼的间隙处理大小适合间隙的支架。 包括TPO在内的支架能够比不含TPO或BMP-2的BMP-2或支架的支架产生更好的结果。 这些数据表明，表现出血小板生成活性的化合物如重组TPO可用于促进哺乳动物的骨生长和愈合。

    PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS
    96.
    发明申请
    PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS 有权
    用于增加血小板水平的肽治疗

    公开(公告)号：US20120094907A1

    公开(公告)日：2012-04-19

    申请号：US13378061

    申请日：2010-06-13

    Applicant: Michal Abraham ,  Amnon Peled ,  Orly Einzenberg

    Inventor： Michal Abraham ,  Amnon Peled ,  Orly Einzenberg

    IPC: A61K38/10 ,  A61K38/19 ,  A61P7/04

    CPC classification number: A61K38/10 ,  A61K38/196 ,  A61K2300/00

    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention relates to compositions and methods for providing improved platelet levels, useful in the treatment and prevention of thrombocytopenia, for controlling bleeding and for inducing or modulating haemostasis.

    Abstract translation: 本发明涉及T-140类似物的新颖治疗用途及其组合物。 具体地，本发明涉及提供改善的血小板水平的组合物和方法，其用于治疗和预防血小板减少症，用于控制出血和诱导或调节止血。

    Therapeutic Uses of Allogeneic Myeloid Progenitor Cells
    99.
    发明申请
    Therapeutic Uses of Allogeneic Myeloid Progenitor Cells 有权
    同种异体骨髓祖细胞的治疗用途

    公开(公告)号：US20110052550A1

    公开(公告)日：2011-03-03

    申请号：US12875022

    申请日：2010-09-02

    Applicant: Janice Marie Brown

    Inventor： Janice Marie Brown

    IPC: A61K35/12 ,  A61P37/00

    CPC classification number: A61K35/15 ,  A61K35/19 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K2300/00

    Abstract: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.

    Abstract translation: 通过移植或输注同种异体骨髓祖细胞（包括CMP，GMP，MEP和MKP细胞亚群）增强骨髓功能。 骨髓祖细胞改善贫血和血小板减少症的后遗症，并可预防或治疗与化疗，放疗等相关的胃肠道粘膜炎。 可以在不存在HLA分型的情况下进行移植或输注，并且细胞可能在一个或多个I类HLA基因座处不匹配。 该移植可以提供治疗正在进行的疾病或预防高危患者的疾病。

    Therapeutic uses of allogeneic myeloid progenitor cells
    100.
    发明授权
    Therapeutic uses of allogeneic myeloid progenitor cells 有权
    同种异体骨髓祖细胞的治疗用途

    公开(公告)号：US07811815B2

    公开(公告)日：2010-10-12

    申请号：US11270710

    申请日：2005-11-08

    Applicant: Janice Marie Brown

    Inventor： Janice Marie Brown

    IPC: C12N5/00 ,  C12N5/02 ,  C12N5/071

    CPC classification number: A61K35/15 ,  A61K35/19 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K2300/00

    Abstract: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.

    Abstract translation: 通过移植或输注同种异体骨髓祖细胞（包括CMP，GMP，MEP和MKP细胞亚群）增强骨髓功能。 骨髓祖细胞改善贫血和血小板减少症的后遗症，并可预防或治疗与化疗，放疗等相关的胃肠道粘膜炎。 可以在不存在HLA分型的情况下进行移植或输注，并且细胞可能在一个或多个I类HLA基因座处不匹配。 该移植可以提供治疗正在进行的疾病或预防高危患者的疾病。

Patent Agency Ranking